Rimadyl for Horses 50 mg/ml Solution for Injection

País: Reino Unido

Idioma: inglés

Fuente: VMD (Veterinary Medicines Directorate)

Ingredientes activos:

Carprofen

Disponible desde:

Pfizer Ltd

Designación común internacional (DCI):

Carprofen

Estado de Autorización:

Expired

Ficha técnica

Revised: May 2008
AN: 02313/2007
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimadyl for Horses 50 mg/ml Solution for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ACTIVE INGREDIENT:_
CARPROFEN
5.0% W/V
_PRESERVATIVE:_
Ethanol
10.0% v/v
For a full list of excipients, see Section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and ponies.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Indicated for analgesic and anti-inflammatory action in
musculo-skeletal disorders and
after surgery.
4.3
CONTRAINDICATIONS
FOR INTRAVENOUS USE ONLY.
For specific information about the time which must elapse between
treatment and
competition, veterinary surgeons are advised to consult the authority
responsible for
the competition in question (e.g. the Jockey Club in the case of
racing in the UK).
Do not exceed the stated dose or the duration of the treatment.
Do not administer other NSAID’s concurrently or within 24 hours of
each other.
Some NSAID’s may be highly bound to plasma proteins and compete with
other
highly bound drugs, which can lead to toxic effects.
Revised: May 2008
AN: 02313/2007
Do not use in animals suffering from cardiac, hepatic or renal
disease, where there is
a possibility of gastro-intestinal ulceration or bleeding, or where
there is evidence of a
blood dyscrasia or hypersensitivity to the product.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in any animal less than 6 weeks of age, or in aged animals may
involve
additional risk. If such a use cannot be avoided, animals may require
a reduced
dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals as
there is a
potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO ANIMALS